A Phase 2 interventional study of Sintilimab and Liposomal Paclitaxel + Cisplatin + S-1 in Esophageal Squamous Cell Carcinoma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-19.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment
This study aims to investigate the safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal cancer.
This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab in combination with liposomal paclitaxel, cisplatin and S-1 will be given every 3 weeks to our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6 weeks after last neoadjuvant treatment. This study will be devided for 3 phases: safety run-in, efficacy pilot and efficacy confirmation.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's enrollment of 30 is below the median of 58 across 1,171 interventional studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 543 studies on the registry; 301 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Histologically or cytologically confirmed esophageal squamous cell carcinoma.
The tumor is located in the middle or lower third of the esophagus ( more than 18cm below incisor), potentially resectable and requiring neoadjuvant therapy (T1b-3, Nany, M0 or T4a, N0-1, M0).
No prior treatment for this disease.
Eastern cooperative oncology group (ECOG) performance status of 0 to 1.
Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol.
Understand and voluntarily sign the informed consent(s).
Patients who are able to complete the treatment and follow-up according to the study plan.
Patients who have sufficient tissue samples and agree to provide their tissue samples and blood samples for detailed analysis.
Female patients in child bearing period must have evidence of negative pregnancy test and agree to take effective contraceptive measures during the study.
Exclusion Criteria:
Patients who may develop tracheoesophageal fistula or aortoesophageal fistula.
Patients suffering from severe malnutrition or needing tube feeding.
Uncured patients with other malignancies within 2 years.
Patients who have active autoimmune diseases or patients who are undergoing treatment of autoimmune diseases.
Patients who need systemic glucocorticosteroid treatment (more than 10mg prednisone daily or other equivalent drugs) within 7 days before the neoadjuvant therapy or other immunosuppressive drugs.
Patients who have immune deficiency.
Patients with active viral or bacterial infection who need systemic treatment within 7 days before the neoadjuvant therapy.
Patients with uncontrolled diabetes mellitus.
Patients with interstitial pulmonary disease, noninfectious pneumonia, or pulmonary fibrosis.
Patients with preexisting symptoms of sensory or motor nerve damage (greater than Grade 1, WHO) .
Patients who have received allogeneic organ or stem cell transplants.
Patients who are allergic to drugs or related ingredients in this study.
Patients who take part in clinical trials of other drugs or biological therapy at present.
Patients with any serious or unstable medical condition or mental illness.
Patients who are dependent on or addicted to alcohol or drugs.
Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
Drug: Sintilimab · Drug: Liposomal Paclitaxel + Cisplatin + S-1
Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
Also known as: IBI308
Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
Also known as: PFC
Safety and feasibility
Safety is defined as the incidence of Grade 3-4 Treatment-Related Adverse Events (TRAEs) from the day of neoadjuvant therapy to 30 days after surgery or within 90 days after last neoadjuvant treatment. Feasibility of surgery is defined as the incidence of TRAEs causing surgery delay of ≥30 days and/or inoperable patients.
Time frame: 20 months
MPR rate
Major Pathological Response (MPR) is defined as the presence of 10% or fewer viable cancer cells in the hematoxylin and eosin (H\&E)-stained slides from the resected tumor following neoadjuvant treatment.
Time frame: 20 months
R0 resection rate
R0 resection is defined as no cancer cells are seen microscopically at the resection margin following surgery.
Time frame: 20 months
Recurrence-Free Survival (RFS)
Recurrence-Free Survival (RFS) is calculated from surgery to the date of recurrence or death.
Time frame: 5 years
Overall Survival (OS)
Overall Survival (OS) is calculated from the beginning of neoadjuvant treatment to the date of death from any cause.
Time frame: 5 years
Exploratory Outcomes
Correlation between biomarkers, including tumor mutational burden (TMB), clonal mutations, genetic alterations, and circulating tumor DNA (ctDNA), and therapeutic response to neoadjuvant therapy will be explored.
Time frame: 20 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University